ImmuneTaisho licenses Japanese rights to Kaigene’s KG-006Kaigene Inc. has entered into a licensing agreement with Taisho Pharmaceutical Co. Ltd. for the exclusive development and commercialization of Kaigene’s next-generation human neonatal Fc receptor (FcRn) inhibitor, KG-006, in Japan.